SLS
Sellas Life Sciences Group IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.54B
P/E Ratio
—
EPS
$-0.23
Beta
2.53
52W High
$9.51
52W Low
$1.39
50-Day MA
$6.26
200-Day MA
$3.78
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Sellas Life Sciences Group Inc
SELLAS Life Sciences Group, Inc., an advanced-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for various indications of cancer in the United States. The company is headquartered in New York, New York.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 900,000 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -43.60% |
| Return on Assets | -25.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.59 |
| Price-to-Book | 14.19 |
| Price-to-Sales (TTM) | 26.90 |
| EV/Revenue | 20.84 |
| EV/EBITDA | -1.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -82.50% |
| Shares Outstanding | $196.63M |
| Float | $185.23M |
| % Insiders | 0.41% |
| % Institutions | 27.62% |
Historical Volatility
HV 10-Day
103.03%
HV 20-Day
122.45%
HV 30-Day
125.56%
HV 60-Day
113.55%
HV Rank
88.9%
Volatility is currently contracting
Analyst Ratings
Consensus ($10.00 target)
1
Strong Buy1
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026